{
    "clinical_study": {
        "@rank": "131088", 
        "arm_group": [
            {
                "arm_group_label": "Melatonin", 
                "arm_group_type": "Active Comparator", 
                "description": "Melatonin 14mg/daily given over 14 days"
            }, 
            {
                "arm_group_label": "sugar pill", 
                "arm_group_type": "Placebo Comparator", 
                "description": "sugar pill given over 14 days"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of the study is to evaluate the effect of Melatonin (in a dosage of 14mg daily)\n      for a better clinical outcome in the period three days post stroke."
        }, 
        "brief_title": "Safety Study of Melatonin in Stroke Patients", 
        "condition": "Acute Ischemic Stroke", 
        "condition_browse": {
            "mesh_term": [
                "Ischemia", 
                "Stroke", 
                "Cerebral Infarction"
            ]
        }, 
        "detailed_description": {
            "textblock": "Stroke is the third most common cause of stroke. The cascade of event is separated into\n      hyperacute,,acute,sub-acute and chronic. In the acute, sub acute state there are mechanisms\n      of inflammation apoptotic death and effect of free radicals. Melatonin was proved to effect\n      these mechanisms and to have a favourable effect in different diseases. The aim of the study\n      is to prove That the use of Melatonin in a higher dosage may have a anti-destructive effect\n      in stoke."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  within 72hours of ischemic stroke\n\n          -  age 18-80\n\n          -  both gender\n\n          -  ability to sign consent form\n\n        Exclusion Criteria:\n\n          -  intra-cerebral bleeding\n\n          -  tumour of brain\n\n          -  multiple sclerosis\n\n          -  s/p craniotomy\n\n          -  known allergy to melatonin"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "140", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 22, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01863277", 
            "org_study_id": "0130-12"
        }, 
        "intervention": [
            {
                "arm_group_label": "Melatonin", 
                "description": "none", 
                "intervention_name": "Melatonin", 
                "intervention_type": "Drug", 
                "other_name": "Melatonin"
            }, 
            {
                "arm_group_label": "sugar pill", 
                "intervention_name": "placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Melatonin"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 24, 2013", 
        "location": {
            "contact": {
                "email": "y_lampl@hotmail.com", 
                "last_name": "Yair Lampl, Prof", 
                "phone": "+972-3-5028513"
            }, 
            "contact_backup": {
                "email": "maryisraelson@gmail.com", 
                "last_name": "Mary Israelson", 
                "phone": "+972-507-704618"
            }, 
            "facility": {
                "address": {
                    "city": "Holon", 
                    "country": "Israel", 
                    "zip": "58100"
                }, 
                "name": "E. Wolfson Medical Center"
            }, 
            "investigator": {
                "last_name": "Yair Lampl, Prof", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Israel"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Double Blind, Placebo Controlled Study to Evaluate the Efficacy of Melatonin in Acute Ischemic Stroke.", 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Israel: Ministry of Health"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Improvement of at least one point on the MRS score", 
            "safety_issue": "No", 
            "time_frame": "3 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01863277"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Wolfson Medical Center", 
            "investigator_full_name": "Dr. Yair Lampl", 
            "investigator_title": "Prof. Yair Lampl", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Wolfson Medical Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Wolfson Medical Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2013"
    }
}